Cardiol Therapeutics Inc Class A
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for … Read more
Market Cap & Net Worth: Cardiol Therapeutics Inc Class A (CRDL)
Cardiol Therapeutics Inc Class A (NASDAQ:CRDL) has a market capitalization of $118.38 Million ($118.38 Million) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #19171 globally and #7075 in its home market, demonstrating a 9.19% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cardiol Therapeutics Inc Class A's stock price $1.06 by its total outstanding shares 111680087 (111.68 Million).
Cardiol Therapeutics Inc Class A Market Cap History: 2019 to 2026
Cardiol Therapeutics Inc Class A's market capitalization history from 2019 to 2026. Data shows change from $394.90 Million to $118.38 Million (-16.13% CAGR).
Index Memberships
Cardiol Therapeutics Inc Class A is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.00% | #528 of 976 |
|
NASDAQ Composite
IXIC
|
$33.26 Trillion | 0.00% | #1761 of 3165 |
Weight: Cardiol Therapeutics Inc Class A's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Cardiol Therapeutics Inc Class A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cardiol Therapeutics Inc Class A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3318.10x
Cardiol Therapeutics Inc Class A's market cap is 3318.10 times its annual revenue
1.01x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $243.46 Million | $78.76K | -$16.20 Million | 3091.20x | N/A |
| 2021 | $206.61 Million | $62.27K | -$25.01 Million | 3318.10x | N/A |
Competitor Companies of CRDL by Market Capitalization
Companies near Cardiol Therapeutics Inc Class A in the global market cap rankings as of March 18, 2026.
Key companies related to Cardiol Therapeutics Inc Class A by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #423 globally with a market cap of $51.97 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #455 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #423 | Zoetis Inc | NYSE:ZTS | $51.97 Billion | $118.15 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.46 |
| #455 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Cardiol Therapeutics Inc Class A Historical Marketcap From 2019 to 2026
Between 2019 and today, Cardiol Therapeutics Inc Class A's market cap moved from $394.90 Million to $ 118.38 Million, with a yearly change of -16.13%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $118.38 Million | +11.13% |
| 2025 | $106.52 Million | -25.48% |
| 2024 | $142.95 Million | +51.84% |
| 2023 | $94.15 Million | +65.29% |
| 2022 | $56.96 Million | -72.43% |
| 2021 | $206.61 Million | -15.14% |
| 2020 | $243.46 Million | -38.35% |
| 2019 | $394.90 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Cardiol Therapeutics Inc Class A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $118.38 Million USD |
| MoneyControl | $118.38 Million USD |
| MarketWatch | $118.38 Million USD |
| marketcap.company | $118.38 Million USD |
| Reuters | $118.38 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.